Biomarker: BCL2

Histology type: type II EC

Country: Poland

Region: Krakow

Study type: Representative postoperative

Followed up time :

Subgroup 1 name : Low- and moderate- grade

Subgroup 1 number: 215

Subgroup 2 name: Non-endometrioid and high-grade

Subgroup 2 number: 127

Conclusion: Compared with low- and moderate-grade endometrioid ECs, non-endometrioid and high-grade endometrioid ECs showed significant DFF40 and BCL2 underexpression. The absence of DFF40 and BCL2 expression negatively affects DFS and OS. Further prospective studies are warranted to assess the potential utility of DFF40 and BCL2 as targets in the diagnosis or treatment of ECs

Sample type : tissue

Sample method: immunohistochemistry

Expression pattern : under expressed(0-1 negative expression, intensity score was multiplied by the cell staining percentage score to obtain the final immunoreactivity score)

Expression elevation: The staining scores for DFF40, BCL2 and DFF45 for each slide in five high-power fields (× 40) using a 0-to-3 scale (0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining) [19, 20]. The cell staining percentage scores for DFF45 and DFF40 were determined as follows: 0 = expression in up to 10% of cells; 1+ = expression in 10–50% of cells; 2+ = expression in 51–80% of cells; and 3+ = expression in over 80% of cells. The cell staining percentage scores for BCL2 were calculated using the scale defined by Yigit et al.: 0 = expression in up to 5% of cells; 1+ = expression in 5%-25% of cells; 2+ = expression in 26%-50% of cells; and 3+ expression in over 50% of cells. The intensity score was multiplied by the cell staining percentage score to obtain the final immunoreactivity score for each protein, which ranged from 0 to 9. Final scores of 0-1 were indicative of negative protein expression, whereas scores of 2-4 were indicative of low protein expression, and scores of 6-9 were indicative of high protein expression.

Statictics: Mean (SD)

Subgroup 1 age: 65.167 ± 6.661

Subgroup 2 age: 71.244 ± 9.599

Funtion Uniprot: Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells (PubMed:1508712, PubMed:8183370). Regulates cell death by controlling the mitochondrial membrane permeability (PubMed:11368354). Appears to function in a feedback loop system with caspases (PubMed:11368354). Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) (PubMed:11368354). Also acts as an inhibitor of autophagy: interacts with BECN1 and AMBRA1 during non-starvation conditions and inhibits their autophagy function (PubMed:18570871, PubMed:21358617, PubMed:20889974). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).

UniProt ID: P10415

UniProt Link: https://www.uniprot.org/uniprotkb/P10415/entry

Biological function from UniProt: Apoptosis

Molecular function from UniProt:

Tissue specificity from UniProt: Expressed in a variety of tissues.

Subcellular UniProt: #Cytoplasm #Endoplasmic reticulum #Membrane #Mitochondrion #Mitochondrion outer membrane #Nucleus

Alternative name from UniProt:

Gene name from HGNC: BCL2 (Bcl-2, PPP1R50)

HPA link: https://www.proteinatlas.org/ENSG00000171791-BCL2

Tissue specificity RNA from HPA: Low tissue specificity

Tissue expression from HPA: Cytoplasmic expression in several different tissue types, including thyroid gland and lymphoid organs.

Subcellular summary HPA Located in Nucleoplasm, Nuclear membrane

Cancer prognostic summary HPA Prognostic marker in renal cancer (favorable), cervical cancer (favorable) and thyroid cancer (unfavorable)

Pathology link: https://www.proteinatlas.org/ENSG00000171791-BCL2/tissue

Pathology endo: https://www.proteinatlas.org/ENSG00000171791-BCL2/tissue/duodenum

Expression figure legend: DFF40*, DFF45**, and BCL2*** expression (× 200) in different histological types of endometrial cancers.

Expression figure link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899339/figure/Fig1/

Survival figure legend: Kaplan-Meier survival curves for overall and disease-free survival in DFF40*-, DFF45**-, and BCL2***-negative and positive cases in the entire study cohort and in Groups A$ and B$$,

Survival curve link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899339/

HGNC ID: HGNC:990

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:990